, Tracking Stock Market Picks
Enter Symbol:
Acorda Therapeutics, Inc. (ACOR) [hlAlert]

Neutral ACOR

Acorda Therapeutics, Inc. (ACOR) rated Neutral with price target $33 by MKM Partners

Posted on: Thursday,  Oct 30, 2014  1:25 PM ET by MKM Partners

MKM Partners rated Neutral Acorda Therapeutics, Inc. (NASDAQ: ACOR) on 10/30/2014. Previously MKM Partners rated Sell Acorda Therapeutics, Inc. (NASDAQ: ACOR) on
05/02/2013., when the stock price was $37.07. Since then, Acorda Therapeutics, Inc. has lost 17.21% as of 11/01/2013's recent price of $30.69.
If you would have followed the previous MKM Partners's recommendation on ACOR, you would have gained 20.78% of your investment in 183 days.

Acorda Therapeutics is commercial-stage biopharmaceutical company dedicated to the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis, spinal cord injury and other disorders of the central nervous system. Acorda currently markets Zanaflex Capsules for the management of spasticity. The Company's lead product candidate, Fampridine-SR, for the improvement of walking ability in persons with multiple sclerosis. It develops therapies that restore neurological function to people with spinal cord injury, multiple sclerosis and related conditions of the nervous system.

MKM Partners LLC is an institutional equity trading and research firm. MKM Partners has extensive experience in the agency execution of U.S. and international equity orders. We provide clients with timely and unbiased economic, technical, and fundamental research.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
10/30/2014 1:25 PM Hold
36.09 33.00
as of 10/17/2014
1 Week   
1 Month   
3 Months   
1 YTD   
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
11/1/2013 11:25 AM Hold
5/2/2013 2:25 PM Sell
4/16/2013 11:25 AM Hold
38.10 33.00
1/8/2013 8:25 AM Hold
1/9/2012 11:25 AM Buy
26.68 32.00
9/20/2011 11:25 AM Hold
22.80 25.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy